Elektronenstoßinduzierter Verlust der Substituenten an C-5 und C-8 bei 1,2,3,4-Tetrahydroisochinolinen, 3. Mitt.1) Synthese C-8-substituierter 5-Ethoxy-6-methoxy-1,2,3,4-tetrahydroisochinoline

Electron-Impact Induced Loss of C-5/C-8 Substituents in the Molecular Ions of 1,2,3,4-Tetrahydroisoquinolines, III: The Synthesis of C-8 Substituted 5-Ethoxy-6-methoxy-1,2,3,4-tetrahydroisoquinolines The synthesis of the title compounds is described.     

Synthesis and pharmacological properties of some 2-(3-aminopropionyl)- and 2-(3-aminopropyl)-1-(3-pyridyl)-1,2,3,4-tetrahydro-beta-carbolines

Five derivatives of 2-(3-aminopropionyl)-1-(3-pyridyl)-1,2,3,4-tetrahydro-beta-carboline (2a-e) were obtained, which yielded, as a result of reduction with LiAlH4, five respective 2-aminopropyl-derivatives (3a-e). Pharmacological studies revealed that phenylpiperazine-derivatives 2d, 2e, 3d and 3e have sedative and analgesic properties. All compounds are devoided of neuroleptic, antidepressant, anxiolytic and antiparkinsonic activity.     

1-(对羟苄基)-N-甲基-6-甲氧基-7-羟基异喹啉对α肾上腺素受体的作用

在大鼠输精管上,BMIQ 10μmol/L和YHB 1μmol/L都能使CLN的量效曲线平行右移,最大反应不变,表明二者均能竞争性地阻断突触前α_2受体,其pA_2值分别为6.69和7.8.大鼠肛尾肌实验表明,BMIQ亦有竞争性拮抗突触后α_1受体作用,pA_2值为5.14。其α_2/α_1阻断作用之比率为35.5,说明BMIQ对α_2受体的选择性大于α_1受体.BMIQ和YHB在毁脊髓大鼠标本上,均能使B—HT920升高舒张血压的量效曲线平行右移,最大反应不变.二者的剂量比率分别为2.7和14.8,且BMIQ抗突触后膜α_2受体作用仅为YHB的1/5.5。     

Synthese des 6,7-Dimethoxy-3-(3,4-dimethoxy-α-hydroxybenzyl)-2-methyl-1,2,3,4-tetrahydroisochinolins

Synthesis of 6,7-Dimethoxy-3-(3,4-dimethoxy-α-hydroxybenzyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline The synthesis and chemical reactivity of 6,7-dimethoxy-3(3,4-dimethoxy-α-hydroxybenzyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline (I) are described.     

Intramolekulare Aromatenalkylierungen, 12. Mitt.1) Synthese von 1-(3-Methylpyridin-2-ylmethyl)-1,2,3,4-tetrahydronaphthalinen

Intramolecular Alkylations of Aromatic Compounds, XII¹⁾: Synthesis of 1-(3-Methylpyridin-2-ylmethyl)-1,2,3,4-tetrahydronaphthalenes Treatment of tetrahydronaphthalenones 10 with 3-methyl-2-picolyllithium (9) yields the tetrahydronaphthalenols 11 , which can be converted into the title compounds 13 by dehydration and subsequent catalytic hydrogenation in a one-pot method. The hydrogenolysis of 11 fails to give 13 immediately. The structures of 11 and 13 were elucidated by ¹H-NMR spectroscopy.     

Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)

Sphingosine 1-phosphate lyase (S1PL) has been characterized as a novel target for the treatment of autoimmune disorders using genetic and pharmacological methods. Medicinal chemistry efforts targeting S1PL by direct in vivo evaluation of synthetic analogues of 2-acetyl-4(5)-(1(R),2(S),3(R),4-tetrahydroxybutyl)-imidazole (THI, 1) led to the discovery of 2 (LX2931) and 4 (LX2932). The immunological phenotypes observed in S1PL deficient mice were recapitulated by oral administration of 2 or 4. Oral dosing of 2 or 4 yielded a dose-dependent decrease in circulating lymphocyte numbers in multiple species and showed a therapeutic effect in rodent models of rheumatoid arthritis (RA). Phase I clinical trials indicated that 2, the first clinically studied inhibitor of S1PL, produced a dose-dependent and reversible reduction of circulating lymphocytes and was well tolerated at dose levels of up to 180 mg daily. Phase II evaluation of 2 in patients with active rheumatoid arthritis is currently underway.     

Production of 1-(1-adamantyl)-2-[4-(2-chloropyrimidinyl)]-1,2,3,4-tetrahydroisoquinoline

A multistage synthesis of a new derivative of 1,2,3,4-tetrahydroisoquinoline is described. Synthesis of title compound is based on the Bischler-Napieralski reaction.     

Antidepressant profile of 9-methyl-2[-3-(4-phenyl-1-piperazinylpropyl)]-1,2,3,4-tetrahydro-beta- carbolin-1-one (B-193)

A potential antidepressant activity of B-193 was studied in mice and rats. In in vitro studies B-193 did not affect the uptake of NA and 5-HT. In in vivo models the tested compound did not influence the reserpine-induced hypothermia, hypoactivity and ptosis, the stimulating action of L-DOPA, the apomorphine-induced hypothermia. On the other hand, it produced a positive effect in the despair test. When given repeatedly, it evoked adaptive changes in brain neurotransmitter receptors, i.e. it decreased the density of beta-adrenoceptors and increased the number of alpha 1 ones; those changes were accompanied with functional alternations in the reactivity of those receptors: an attenuated behavioral reaction to salbutamol and enhanced aggressiveness induced by a high dose of clonidine. Furthermore, B-193 administered repeatedly enhanced hyperlocomotion induced by amphetamine but did not influence the stereotypy induced by apomorphine. These results indicate that B-193 possesses properties characteristic for atypical antidepressants.     

Antiserotonin activity of 9-methyl-2-[3-(4-phenyl-1-piperazinylpropyl)]-1,2,3,4-tetrahydro -beta-carbolin-1-one (B-193)

The effect of B-193 on the central and peripheral serotonin system was studied. B-193 antagonized the head-twitches responses induced by L-5-hydroxytryptophan (L-5-HTP) in mice (ED50 = 0.75 mg/kg ip and 6.6 mg/kg po) and lysergic acid diethylamide (LSD) in rats (ED50 = 1.54 mg/kg ip) and also counteracted forepaws clonic convulsions induced by tryptamine (ED50 = 3.07 mg/kg ip). B-193 (2.5-20 mg/kg ip) antagonized dose-dependently hyperthermia induced by fenfluramine or m-chlorophenylpiperazine (m-CPP) and in a dose of 1 mg/kg iv abolished the stimulation of the flexor reflex evoked by quipazine or fenfluramine. B-193 given in a concentration of 10(-7)-10(-5) mol/l competitively inhibited contractions of the rat stomach fundus strip induced by serotonin (5-HT) (pA2 = 6.5) and the increases in blood pressure induced by 5-HT in pithed rats (ED50 = 0.17 mg/kg iv). In receptor binding studies B-193 has shown distinct affinity to 5-HT2 receptors, and alpha 1-adrenoceptors much weaker affinity to 5-HT1 receptors and alpha 2-adrenoceptors but not to beta-adrenergic, GABA-ergic or benzodiazepine receptors. Our findings demonstrated that B-193 shows potent central and peripheral antiserotonin activity.     

1—（4—胺乙酰胺基）苄基四氢异喹啉类化合物的合成及其心血管活性

研究发现某些异喹啉类化合物具有较好的心血管活性，Ｎ胺乙酰基取代的苄基四氢异喹啉化合物对二氢吡啶（ＤＨＰ）受体有较好的亲和力〔１〕．据报道〔２〕化合物１（２乙胺基乙酰胺基３，４二甲氧基）苄基异喹啉具有较强的抗心律失常作用，毒性远低于利多卡因．...     

Conformationally restricted phenothiazine neuroleptics. 1. 3-(Dimethylamino)-1,2,3,4-tetrahydroazepino[3,2,1-kl]phenothiazine

A rigid analogue of promazine, 3-(dimethylamino)-1,2,3,4-tetrahydroazepino[3,2,1-kl]phenothiazine (1), was prepared by reductive amination of the corresponding ketone 4. An X-ray crystallographic study revealed that the seven-membered ring of the hydrochloride salt of 1 exists as a half-chair-like form with the dimethylammonium group in an equatorial-like conformation. Compound 1 was approximately one-half as active as promazine as an inhibitor of [3H]spiperone binding in rat corpus striatal homogenates. In homogenates obtained from calf caudate tissue, however, 1 was only about one-twentieth as active as promazine as an inhibitor of [3H] spiperone binding. As a stimulator of homovanilic acid (HVA) synthesis in rat corpus striatum in vivo, it was about one-tenth as active as promazine.     

Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist

(3R)-7-Hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) was identified as a potent and selective kappa opioid receptor antagonist. Structure-activity relationship (SAR) studies on JDTic analogues revealed that the 3R,4R stereochemistry of the 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine core structure, the 3R attachment of the 7-hydroxy-1,2,3,4-tetrahydroisoquinoline group, and the 1S configuration of the 2-methylpropyl (isopropyl) group were all important to its kappa potency and selectivity. The results suggest that, like other kappa opioid antagonists such as nor-BNI and GNTI, JDTic requires a second basic amino group to express potent and selective kappa antagonist activity in the [(35)S]GTPgammaS functional assay. However, unlike previously reported kappa antagonists, JDTic also requires a second phenol group in rigid proximity to this second basic amino group. The potent and selective kappa antagonist properties of JDTic can be rationalized using the "message-address" concept wherein the (3R,4R)-3,4-dimethyl-4-(hydroxyphenyl)piperidinyl group represents the message, and the basic amino and phenol group in the N substituent constitutes the address. It is interesting to note the structural commonality (an amino and phenol groups) in both the message and address components of JDTic. The unique structural features of JDTic will make this compound highly useful in further characterization of the kappa receptor.     

Asymmetrische elektrophile α-Amidoalkylierung, 8. Mitt.: Gewinnung optisch aktiver α-Phenacylpyrrolidinamide und erste asymmetrische Totalsynthese des Norruspolins

Asymmetric Electrophilic α-Amidoalkylation, VIII¹): Syntheses of Optically Active α-Phenacylpyrrolidinamides and First Asymmetric Total Synthesis of Norruspoline The α-phenacyl pyrrolidinamides (R)- 4 /(S)- 5a-e are prepared stereoselectively by reaction of the chiral non racemic α-methoxyamide 1 with silyl enolethers 2a-d . The geminal bisamides (R)- 12 /(S)- 13 are formed from 1 and the bistrimethylsilyl imidate 11 . (R)- 4d is employed in the synthesis of optically active norruspoline (R)- 16 (ee ≧ 84%).